TG Therapeutics Reports Strong Q1 2026 Results, Secures $500M Non-Dilutive Capital, and Expands Share Buyback to $300M

summarizeSummary

TG Therapeutics reported strong Q1 2026 financial results, including significant revenue and net income growth, bolstered by a new $500 million non-dilutive capital raise and an expanded $300 million share repurchase program.

check_boxKey Events

• Strong Q1 2026 Financial Performance

  Net income for the three months ended March 31, 2026, significantly increased to $19.7 million, up from $5.0 million in the prior year period. Product revenue, net, grew to $201.3 million from $119.7 million, primarily driven by U.S. sales of BRIUMVI.

• Enhanced Liquidity with Non-Dilutive Capital

  The company secured a new $750 million senior secured credit facility, repaying an existing $250 million facility, resulting in a net non-dilutive capital raise of $500 million. This boosted cash and cash equivalents to $442.2 million as of March 31, 2026, compared to $79.1 million at year-end 2025.

• Expanded Share Repurchase Program

  The Board of Directors authorized an increase to the share repurchase program from $100 million to $300 million. The company repurchased approximately $100.0 million of common stock during Q1 2026 at an average price of $30.44 per share.

• Product Pipeline Advancement

  Phase 3 enrollment for subcutaneous BRIUMVI has been completed, with topline data anticipated around year-end 2026 or Q1 2027. The Phase 1 trial for Azer-cel in progressive multiple sclerosis is also actively enrolling patients.

auto_awesomeAnalysis

This 10-Q filing details TG Therapeutics' robust financial performance for Q1 2026, confirming and elaborating on the positive announcements made in an earlier 8-K filing today. The company reported a significant increase in net income and product revenue, driven by strong sales of BRIUMVI. Critically, the company secured a new $750 million non-dilutive senior secured credit facility, resulting in a net capital raise of $500 million, substantially boosting its cash reserves. Concurrently, the Board expanded the share repurchase program to $300 million, demonstrating confidence in future cash flows and a commitment to shareholder returns. These financial and capital actions, coupled with progress in its product pipeline, including the completion of Phase 3 enrollment for subcutaneous BRIUMVI, position the company strongly for continued growth and operational stability.